Teva ends deal with Sosei to develop CGRP antagonists for treatment of migraine

Teva terminated a 2015 agreement with Sosei's Heptares Therapeutics unit giving it exclusive rights to develop, manufacture and market small-molecule CGRP antagonists for the treatment of migraine and other severe headaches, Sosei reported Tuesday. According to Sosei, which will regain rights to all of the programmes, including lead candidate HTL0022562, Teva made the decision following a recent portfolio prioritisation.

Sosei noted that Teva was expected to initiate Phase I development of HTL0022562 by the end of the year. Sosei indicated that it will complete a detailed review of the anti-CGRP programmes and provide an update on the anticipated start studies of HTL0022562 later this year.

FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

The decision by Teva comes after the Israeli drugmaker acknowledged last month that US approval of the anti-CGRP drug fremanezumab would likely delayed by an FDA warning letter received by partner Celltrion. Teva had previously expressed plans to launch the treatment in the US this year after it was awarded priority review by the FDA last December.

For related analysis, see ViewPoints: Teva's dire straits show first signs of straightening.

To read more Top Story articles, click here.